Interferons and bladder cancer

Urologic Clinics of North America

Volumn 27, Issue 1, 2000, Pages 171-178

  Brown, David Hugh ^b   Wagner, Theodore T ^b   Bahnson, Robert R ^b  

^a Division of Urology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; INTERFERON;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELLULAR IMMUNITY; DRUG TOLERABILITY; HUMAN; HUMORAL IMMUNITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0033961044     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70245-7     Document Type: Article

References (45)

1. R.R. Bahnson T.L. Ratliff Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo J Urol 144 1988 656
2. R. Bartoletti G. Massimini D. Criscuolo Interferon alpha 2a in superficial bladder cancer prophylaxis: Toleration and long-term follow-up. A phase I-II study Anticancer Res 11 1991 2167
3. E. Bercovich M. Deriu F. Manferrari BCG vs BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder Arch Ital Urol Androl 67 1995 257
4. F. Boccardo D. Cannata A. Rubagotti Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study J Clin Oncol 12 1994 7
5. E.C. Borden D.S. Groveman T. Nasu Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro J Urol 132 1984 800
6. J.E. Coe J.D. Feldman Extracutaneous delayed hypersensitivity, particularly in guinea pig bladder Immunology 10 1966 127
7. P. Conti M. Reale M. Nicolai BCG potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not to interleukin-6 in bladder cancer patients Cancer Immunol Immunother 38 1994 365
8. S.M. DiStasi G. Vergilli G. Vespasiani Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder: A pilot study Br J Urol 71 1993 422
9. T. Downs A. Szilvasi M.A. O'Donnell Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2b J Urol 158 1997 2311
10. M.J. Droller D. Gomolka Enhancement of natural cytoxicity in lymphocytes from animals with carcinogen-induced bladder cancer J Urol 129 1983 625
11. U. Engelmann H.J. Knopf J. Graff Interferon-alpha 2b installation prophylaxis in superficial bladder cancer—a prospective, controlled three-armed trial: Project Group Bochum—interferon and superficial bladder cancer Anticancer Drugs 3 1992 33
12. P. Ferrari G. Castagnetti C. Pollastri Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: Interferon-alpha 2b versus interferon-alpha 2b with epirubicin Anticancer Drugs 3 1992 25
13. A.D.H. Geboers T.N.L.M. van Bergen W. Oosterlinck Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer J Urol 137 1987 276
14. S. Giannakopoulos A. Gekas G. Alivizatos Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma Br J Urol 82 1998 829
15. R.W. Glashan A randomized controlled study of intravesical alpha-2b interferon in carcinoma in situ of the bladder J Urol 144 1990 658
16. K. Gohji M. Nomi M. Okamoto Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder Urology 53 1999 308
17. J.W. Grups H.G. Frohmuller R. Ackermann Can recombinant human alpha-2 interferon prevent recurrence of high-grade superficial bladder tumors? Cancer Detect Prev 10 1987 405
18. M.A. Hudson H.W. Herr Carcinoma in situ of the bladder J Urol 153 1995 564
19. D. Ikic P. Nola Z. Maricic Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma Lancet 1 1981 1022
20. C.D. Jurinicic U. Englemann J. Gasch Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: A randomized study J Urol 139 1988 723
21. A. Kostakopoulos C. Deliveliotis E. Mavromanolakis Intravesical interferon alpha-2b administration in the treatment of superficial bladder tumors Eur Urol 18 1990 201
22. D.L. Lamm J.I. DeHaven D.R. Riggs Immunotherapy of murine bladder cancer with keyhole-limpet hemocyanin (KLH) J Urol 149 1993 648
23. D.L. Lamm A. Morales H.B. Grossman Keyhole limpet hemocyanin (KLH) immunotherapy of papillary and in situ transitional cell carcinoma of the bladder: A multi-center phase I-II clinical trial [abstract] J Urol 155 1996 1405
24. S. Landis T. Murray S. Bolden Cancer statistics, 1999 CA Cancer J Clin 49 1999 12
25. P.U. Malmstrom H. Wijkstrom C. Lundholm 5-Year follow up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma J Urol 161 1999 1124
26. R. Migliari M. el Demiri G. Muscas Intravesical installation of beta-interferon in the treatment of bladder cancer Br J Urol 70 1992 169
27. A. Morales D. Eidenger A.W. Bruce Intracavitary bacillus Calmette-Guerin in the treatment of superficial tumors J Urol 116 1976 127
28. T. Niijima Intravesical treatment of bladder cancer with recombinant human interferon-beta: Intravesical GKT-beta chemotherapy research group Cancer Immunol Immunother 30 1989 81
29. R.T.D. Oliver J.H. Waxman H. Kwok Alpha lymphoblastoid interferon for noninvasive bladder cancer Br J Cancer 53 1986 432
30. S.S. Ottesen V. Ahrenkiel J. Kieler Recombinant human interferon-gamma exerts an antiproliferative effect and modulates the expression of human leukocyte antigens A, B, C, and DR in human urothelial cell lines Cancer Immunol Immunother 31 1990 93
31. J.J. Patard F. Saint F. Velotti Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: A review Urol Res 26 1998 155
32. M. Pavone-Macaluso M. Tripi G.B. Ingargiola Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer: The present role of epirubicin and doxorubicin J Chemother 5 1993 207
33. R. Pearl Cancer and tuberculosis 9 1929 97
34. J. Portillo B. Martin R. Hernandez Results at 43 months' follow up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder Urology 49 1997 187
35. M.P. Raitanen O. Lukkarinen A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder: Finnish Multicentre Study Group Br J Urol 76 1995 697
36. T.L. Ratliff L.R. Kavoussi W.J. Catalona Role of fibronectin in intravesical BCG therapy for superficial bladder cancer J Urol 139 1988 410
37. T.L. Ratliff D. Kadmon A. Shapiro Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta Cancer Res 44 1984 4377
38. D.R. Riggs W.F. Tarry J.I. DeHaven Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy J Urol 147 1992 212
39. M.F. Sarodsy Principles of intravesical chemotherapy and immunotherapy Urol Clin North Am 19 1992 509
40. M.F. Sarodsy C.A. Kierum Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone J Urol 142 1989 1376
41. M.F. Sarodsy D.L. Lamm R.D. Williams Phase I trial of oral bropirimine in superficial bladder cancer J Urol 147 1992 31
42. M.F. Sarodsy B.A. Lowe P.F. Schellhammer Oral bropirimine immunotherapy of carcinoma in situ of the bladder: Results of a phase II trial Urology 48 1996 21
43. C.H. Scorticatti N.C. de la Pena O.G. Bellora Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: Pilot study J Interferon Res 2 1982 339
44. P. Stricker K. Pryor T. Nicholson Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer Urology 48 1996 957
45. F.M. Torti L.D. Shortliffe R.D. Williams Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study J Clin Oncol 6 1988 476